Palmitoylation of NLRP3 Modulates Inflammasome Activation and Inflammatory Bowel Disease Development
The Journal of Immunology · 15.08.2024 · 213 (4) · 481-493
DOI: 10.4049/jimmunol.2300241 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 01.07.2024. Verfasst von Dingwen Hu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Experimental Center, Jiangmen Central Hospital, Jiangmen, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Lipoylation, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Guangdong academy of medical science, National nature science foundation of China, Key-Area Research and Development Program of Guangdong Province.
Abstract (Originalsprache)
Aberrant activity of NLRP3 has been shown associations with severe diseases. Palmitoylation is a kind of protein post-translational modification, which has been shown to regulate cancer development and the innate immune system. Here, we showed that NLRP3 is palmitoylated at Cys419 and that palmitoyltransferase ZDHHC17 is the predominant enzyme that mediates NLRP3 palmitoylation and promotes NLRP3 activation by interacting with NLRP3 and facilitating NIMA-related kinase 7 (NEK7)–NLRP3 interactions. Blockade of NLRP3 palmitoylation by a palmitoylation inhibitor, 2-bromopalmitate, effectively inhibited NLRP3 activation in vitro. Also, in a dextran sulfate sodium–induced colitis model in mice, 2-bromopalmitate application could attenuate weight loss, improve the survival rate, and rescue pathological changes in the colon of mice. Overall, our study reveals that palmitoylation of NLPR3 modulates inflammasome activation and inflammatory bowel disease development. We propose that drugs targeting NLRP3 palmitoylation could be promising candidates in the treatment of NLRP3-mediated inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Experimental Center, Jiangmen Central Hospital, Jiangmen, China.
- State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China.
- Laboratory Animal Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.
- Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
ORCID-Profile: Kailang Wu
Förderung
- Guangdong academy of medical science
- National nature science foundation of China
- Key-Area Research and Development Program of Guangdong Province
- Guangzhou University of Chinese Medicine First-class universities and Top Disciplines Scientific Research Team Projects
Zitieren
APA
Hu, D., Li, Y., Wang, X., Zou, H., Li, Z., Chen, W., Meng, Y., Wang, Y., Li, Q., Liao, F., Wu, K., Wu, J., Li, G., & Wang, W. (2024). Palmitoylation of NLRP3 Modulates Inflammasome Activation and Inflammatory Bowel Disease Development. The Journal of Immunology, 213(4), 481-493. https://doi.org/10.4049/jimmunol.2300241
Vancouver
Hu D, Li Y, Wang X, Zou H, Li Z, Chen W, et al. Palmitoylation of NLRP3 Modulates Inflammasome Activation and Inflammatory Bowel Disease Development. The Journal of Immunology. 2024;213(4):481-493. doi:10.4049/jimmunol.2300241
BibTeX
@article{Hu2024,
author = {Hu, Dingwen and Li, Yuting and Wang, Xianyang and Zou, Haimei and Li, Zonghui and Chen, Weijie and Meng, Yu and Wang, Yingchong and Li, Qin and Liao, Feng and Wu, Kailang and Wu, Jianguo and Li, Geng and Wang, Wenbiao},
title = {Palmitoylation of NLRP3 Modulates Inflammasome Activation and Inflammatory Bowel Disease Development},
journal = {The Journal of Immunology},
year = {2024},
volume = {213},
number = {4},
pages = {481--493},
doi = {10.4049/jimmunol.2300241}
}
EUVIMED